Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
GLP-1, GIP
Retatrutide led to dose-dependent reductions in body weight of up to 24.2% at 48 weeks, with a safety profile comparable to other GLP-1-based therapies. Jastreboff et al., NEJM Secondary Benefits Improved HbA1c in both diabetic and pre-diabetic participants Significant reductions in liver fat (a marker for NAFLD/NASH reversal) Lowered triglycerides, LDL, and inflammatory markers Favorable impact on blood pressure and fasting insulin levels Tolerability and Safety Most side effects were GI-related and dose-dependent : Nausea Constipation Occasional vomiting All were similar in frequency and severity to those seen in Semaglutide trials No serious adverse events were reported Dropout rates were low across all dose groups These results suggest Retatrutide may offer not only more dramatic weight loss , but also better metabolic improvements and potential muscle-sparing advantages making it a standout candidate for both medical and performance-focused applications
These can be helpful for targeting specific dark spots
Insulin is a hormone that manages sugar and fat (energy) in the bloodstream by moving it into the cells for storage or to burn for energy
Lancet 402 , 693704 (2023)
Blood thinning effects: Anticoagulants can cause the donor to bleed excessively at the needle site
